SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following Saudi Arabia's approval of its Anktiva-based Bioshield protocol for non-small cell lung cancer and broader cancer treatment, alongside ongoing discussions with the FDA for papillary bladder cancer. The community is passionately discussing the potential for a significant short squeeze, viewing the company as a disruptive force in oncology while expressing strong frustration with perceived FDA delays.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz following a substantial upward revision to its future revenue outlook and a surging order backlog, further bolstered by a recent large capital raise. The community is actively discussing its promising potential as a rapidly expanding defense and autonomy platform, especially amidst ongoing negotiations for key acquisitions in the critical drone technology sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending amidst intense debate spurred by former President Trump's controversial push for tariffs against European nations, reportedly tied to his interest in Greenland and past grievances. This situation has ignited polarized community discussions concerning potential trade wars and geopolitical repercussions, with many weighing economic stability against his "America First" agenda.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is trending due to a significant surge in natural gas futures, driven by widespread forecasts for severe arctic cold fronts across the US, intensifying heating demand expectations. The community is actively debating the potential for a powerful short squeeze amidst historically high short interest, while also acknowledging the inherent volatility and decay of leveraged natural gas ETFs like $BOIL, often referred to as a "widow maker". Discussions highlight the impact of this weather event on depleting storage levels, yet some remain cautious, pointing to broader warm winter trends and structural factors like contango, questioning the rally's sustainability.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Oppenheimer said that a challenging operating environment due to the artificial intelligence technology transition has led to “uninspiring and decelerating top-line growth.”&nbsp;</li><li>However, the analyst added that Adobe has good medium-term opportunities and is a cheap stock.&nbsp;</li><li>Earlier, Goldman Sachs assumed coverage of Adobe with a ‘Sell’ rating and a price target of $290.</li></ul>Shares of Adobe Inc. (ADBE) declined nearly 6% on Tuesday after Oppenheimer downgraded the stock to ‘Perform’ from Outperform, without a price target, However, retail traders continue to stay bullish on the stock.Analyst Brian Schwartz at Oppenheimer said that a challenging operating environment due to the artificial intelligence technology transition has led to “uninspiring and decelerating top-line-growth,” according to TheFly.The analyst added that inconsistent execution with product cycles, durability concerns about the moat, lackluster investor interest for owning software names, and year-over-year operating margin guidance in FY26 will likely weigh negatively on the sentiment for the company's opportunities this year, and limit near-term upside for the shares.Shares of ADBE were trading around $308.06 at the time of writing, the lowest it has been in over three years.<h2 class="st-heading-2">Street Consensus</h2>Oppenheimer had previously been bullish on Adobe, expecting its AI business to boost growth in its digital media segment. However, the analyst noted that it did not play out as expected and growth in the digital media growth decelerated further in FY25.However, the analyst added that Adobe has good medium-term opportunities and is a cheap stock.Earlier, Goldman Sachs assumed coverage of Adobe with a ‘Sell’ rating and a price target of $290. The analyst noted that Adobe's high-end seat count is under pressure as value accrues at the low-end where the company has minimal exposure.Adobe’s consensus rating, which indicates the ratio of buy, hold, and sell ratings from analysts, is at 3.73, down from 4 in December 2025, as per data from Koyfin. 22 of 40 analysts still have a rating of ‘Buy’ or higher on the stock.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_at_12_48_07_AM_png_93d2f946b3.webp" alt="Adobe’s consensus rating, which indicates the ratio of buy, hold, and sell ratings from analysts, is at 3.73, down from 4 in December 2025, as per data from Koyfin." width="913" height="772"></figure><h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ADBE">ADBE stock</a> jumped to ‘bullish’ from ‘bearish’ territory over the past 24 hours amid ‘high’ message volumes. Despite the downturn, some retail investors are still bullish on the stock, seeing an attractive long-term opportunity.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_at_12_49_42_AM_png_84db19bff6.webp" alt="On Stocktwits, retail sentiment around ADBE stock jumped to ‘bullish’ from ‘bearish’ territory over the past 24 hours amid ‘high’ message volumes." width="1278" height="154"></figure>&nbsp;One user called Adobe ‘the best creative software in the market’, adding that they would be buying more shares.<stembedurl>https://stocktwits.com/Kaizen777/message/641681297</stembedurl>&nbsp;Another bullish user pointed out that the company has been increasingly buying back its own shares, indicating its confidence.<stembedurl>https://stocktwits.com/2ktrading/message/641686631</stembedurl>&nbsp;Shares of ADBE are down over 24% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A sign is posted on the exterior of an Adobe office on December 10, 2025 in San Francisco, California. Software maker Adobe will report fourth-quarter earnings today after the closing bell. 

ADBE Shares Slip On Analyst Downgrades — But Why Is Retail Bullish?

Adobe shares declined on Tuesday after Oppenheimer downgraded the stock to ‘Perform’ from Outperform, without a price target. 

Equity

Vanguard Growth ETF Portfolio (TSE:VGRO) Hits New 1-Year High - Still a Buy?

Vanguard Growth ETF Portfolio (TSE:VGRO) Reaches New 1-Year High - Here's What Happened...

Vanguard Growth ETF Portfolio (TSE:VGRO) Hits New 52-Week High - Still a Buy?

Vanguard Growth ETF Portfolio (TSE:VGRO) Sets New 12-Month High - Time to Buy...

VUG Fundamental Analysis

Below is Validea's ETF fundamental report for Vanguard Growth ETF (VUG). The report looks at VUG's exposure to the major investing factors including value, quality, momentum and low volatility...

Will the Ongoing Market Rally Continue in 2026? ETFs in Focus

S&P 500 momentum and retail inflows set the stage for a potential 2026 rally, with ETFs offering ways to ride the bullish trend.

VUG vs. VOOG: Which of These Vanguard Growth ETFs Is Best for Investors?

Key PointsVUG is far larger and more liquid than VOOG, but carries slightly higher volatility and a deeper five-year drawdown...

Vanguard Growth ETF vs. Vanguard Value ETF: Which ETF Will Outperform in 2026?

Key PointsGrowth stocks are set to outperform value stocks once again in 2025...

ETFs to Keep Your Portfolio on Track in the Long Term

Despite November's volatility, optimism is returning to Wall Street. Discover how long-term strategies combined with ETFs can help investors build resilient portfolios ready to capture the next phase of the bull market.

S&P 500 Stability vs. Superior Growth: Is VOO or VUG the Better ETF for You?

Key PointsThe Vanguard Growth ETF boasts higher recent returns and greater tech sector exposure, while the Vanguard S&P 500 ETF spreads risk more broadly across 500 companies...

Prediction: This Unstoppable Vanguard ETF Will Crush the S&P 500 (Again) in 2026

Key PointsThe S&P 500 is having a strong year in 2025, but investors who own the Vanguard Growth ETF are doing even better...

VUG
Vanguard Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VUG News

VUGVanguard Growth ETF